US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

710.58

+24.843.62%

Number of Gainers:84

Number of Losers:59

Number of Flat:11

PE:- -

High:710.84

Open:685.68

Low:683.13

Close:685.75

Volume:329.26M

Turnover:10.37B

Market Cap:495.36B

Float Cap:376.11B

Loading ...

Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

ProMIS Neurosciences Q2 Net Loss Widens

Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million

DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate

Benzinga Earnings

Invivyd Q2 EPS USD -0.14

Dlocal Q2 Tpv $17.70 Bln

THOMSON REUTERS

Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year

THOMSON REUTERS

Dlocal Q2 Gross Margin 32%

THOMSON REUTERS

Dlocal Q2 EPS $0.18

THOMSON REUTERS

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

THOMSON REUTERS

Rani Therapeutics Q2 Operating Expenses USD 10.536 Million

THOMSON REUTERS

Press Release: dLocal Reports Second Quarter 2026 Financial Results

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

1stDibs Executives Present at Midwest IDEAS Investor Conference

Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

Sector Update: Financial

MT Newswires Live

Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/BK4539/news?page=37"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":710.5842,"timestamp":1787687999999,"preClose":685.7458,"halted":0,"volume":329259151,"delay":0,"changeRate":0.036221,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":24.83844,"latestTime":"08-25 16:00:00 EDT","open":685.6775,"high":710.84143,"low":683.1322,"amount":10370226198.826471,"amplitude":0.040407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.436531,"peRate":156.391987,"turnoverRate":0.025545,"increases":84,"decrements":59,"flats":8,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":710.84143,"amplitude":0.040407,"preClose":685.7458,"low":683.1322,"pbRate":"5.436531","latestPrice":710.5842,"volume":329259151,"delay":0,"open":685.6775,"prevYearClose":881.5255,"prevWeekClose":700.9769,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":655.4622,"twentyDayClose":704.4272,"sixtyDayClose":779.4826,"secType":"PLATE","market":"US","turnoverRate":0.025545,"peRate":156.391987,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375,"timestamp":1787687999999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":84,"down":59,"flat":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:37,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659273162","title":"Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659273162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659273162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:13","pubTimestamp":1786652037,"startTime":"0","endTime":"0","summary":"Caribou Biosciences Q2 FY26 GAAP net loss narrows to USD 24.3 million; revenue falls to USD 1.5 millionCaribou Biosciences posted a GAAP net loss of USD 24.3 million, or USD 0.24 per share, in Q2 2026.Loss narrowed from USD 54.1 million, or USD 0.58 per share, a year earlier, which included USD 21.3 million in non-cash impairment.Revenue fell 43.8% to USD 1.5 million versus Q2 2025.R&D expenses dropped 31.6% to USD 18.9 million, due to lower external CMO/CRO activity and prior workforce reduction.Cash, cash equivalents and marketable securities totaled USD 113.8 million; runway expected to extend to end-2027, with funding options explored for ANTLER-3.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLc0p1ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CRBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162218","title":"Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162218","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162218?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:12","pubTimestamp":1786651973,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 2026 revenue was zero, down from prior-year periodNet loss for Q2 widened yr/yr as operating expenses in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","CLRB","BK4563","BK4139","INBX","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162415","title":"ProMIS Neurosciences Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162415?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651823,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Q2 net loss widensOverviewUS biotechnology firm's Q2 net loss widened yr/yrCash and short-term investments rose to $53.4 mln, funding operations through 2027Company reported posit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGX","BK4539","ABOS","ANNX","BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162468","title":"Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162468","media":"Reuters","labels":["shareholding","corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162468?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651818,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 millionRani Therapeutics posted a Q2 net loss of USD 8.4 million, narrowing from USD 11.2 million a year earli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLBssyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162939","title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162939","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162939?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651584,"startTime":"0","endTime":"0","summary":"DLocal (NASDAQ:DLO) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 28.57 percent increase over earnings of $0.14 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61192214/dlocal-q2-eps-0-18-misses-0-19-estimate-sales-399-664m-beat-368-858m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4227","BK4539","BK4106","DLO","BK4563","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659626931","title":"Invivyd Q2 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2659626931","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659626931?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651563,"startTime":"0","endTime":"0","summary":"BRIEF-Invivyd Q2 EPS USD -0.14Aug 13 (Reuters) - Invivyd Q2 net income USD -44.393 million.Q2 revenue USD 14.285 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXFW5MJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVVD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659682162","title":"Dlocal Q2 Tpv $17.70 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2659682162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659682162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4227","BK4539","BK4106","DLO","BK4563","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659621521","title":"Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2659621521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659621521?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4106","BK4585","DLO","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659368162","title":"Dlocal Q2 Gross Margin 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659368162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659368162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4106","BK4585","DLO","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162653","title":"Dlocal Q2 EPS $0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162653?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DLO","BK4539","BK4588","BK4585","BK4106","BK4227","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659522162","title":"Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659522162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659522162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA4MLGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162345","title":"Rani Therapeutics Q2 Operating Expenses USD 10.536 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162345?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXRNXP6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616261","title":"Press Release: dLocal Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616261?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"quarter of 2026, up 92% year-over-year compared to US$9.2 billion in the. second quarter of 2025 and up 26% compared to US$14.1 billion in the. first quarter of 2026. In constant currency, TPV growth for the period. -- Revenues amounted to US$399.7 million, up 56% year-over-year compared to. US$256.5 million in the second quarter of 2025 and up 19% compared to. US$335.9 million in the first quarter of 2026. In constant currency,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4106","BK4563","BK4227","DLO","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4568","BK4022","GDOC","BK4551","BK4535","BK4232","BNTX","BK4548","HYLG","BK4139","IND","MEDX","IVVD","IDNA","NVIB","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LFSC","CAR","TBXU","SYNB","PFS","CR","BK4230","BK4161","HYLG","LD","NVIB","BK4022","BK4585","BK4139","IDNA","GNOM","GDOC","MEDX","ORR","CRBU","IBB","BK4588","FBT","CNCR","BK4539","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162046","title":"Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162046","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162046?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Aug.  13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344905/0/en/mineralys-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LCLG","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516475","title":"1stDibs Executives Present at Midwest IDEAS Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516475?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651215,"startTime":"0","endTime":"0","summary":"1stDibs executives present at Midwest IDEAS Investor Conference1stDibs will present at the Midwest IDEAS Investor Conference in Chicago on Aug. 26 at 10:15 a.m. ET.CEO David Rosenblatt will appear alo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLChdld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4220","DIBS","BK4539","BK4122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659641571","title":"Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2659641571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659641571?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:35","pubTimestamp":1786649725,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00. De...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RCC","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164651","title":"Sector Update: Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164651?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:17","pubTimestamp":1786648660,"startTime":"0","endTime":"0","summary":"Financial stocks were higher in late Thursday afternoon trading, with the NYSE Financial Index and the State Street Financial Select Sector SPDR ETF  each adding 0.5%.The Philadelphia Housing Index added 0.7%, and the State Street Real Estate Select Sector SPDR ETF  climbed 1.4%.Bitcoin  was fractionally lower at $63,401, and the yield for 10-year US Treasuries fell 4.1 basis points to 4.641%.In corporate news, Robinhood  plans to accelerate the pace of debuts for its publicly traded closed-end funds after its first two attempts to make private firms more accessible to its retail customers, Bloomberg reported, citing an interview with Robinhood CFO Shiv Verma. Robinhood shares were up 4.6%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFII","CRPT","XLRE","CBOA","MAXI","BPI","CBOJ","HOOY","BK4585","BTC","CBTO","BITI","BITB","BITU","CBOY","HOOD","YBTC","HODU","EZBC","FINX","BITY","FBTC","BPAY","BTC.USD.CC","BTFX","MNRS","HOOX","BK4547","LU1861559042.SGD","IAI","BETE","BTRN","HOII","BITX","HOOI","LU1861558580.USD","XLF","BTCO","IBIT","HOYY","CBTJ","BTCZ","HOOW","HODL","ARKB","BK4539","BCCC","CBXO","SBIT","GBTC","BLCK","BAGY","CBXA","BTCC","BITO","BTCW","BTF","BTCL","CBOO","HOOG","CBXY","BFAP","HOOZ","BFJL","BK4127","BETH","ROBN","BRRR","BK4588","CBXJ","CBTA","XBTY","DEFI","CBTY","QBF","BTCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161715","title":"Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161715","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659161715?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:40","pubTimestamp":1786646403,"startTime":"0","endTime":"0","summary":"Global-e CEO Amir Schlachet sells 16,814 shares for $713,890.60Global-e Online CEO Amir Schlachet sold 16,814 ordinary shares on Aug. 12, 2026 at USD 42.41.Direct holdings stood at 3,948,286 ordinary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLcWRCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4122","BK4539","BK4220","BK4585","BK4588","GLBE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":51,"pageCount":37,"totalSize":1014,"code":"91000000","status":"200"}]}}